Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine Formulations

NCT07089706 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07089706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07089706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine Formulations
Lead sponsor
ModernaTX, Inc.
Phase
Phase 4
Overall status
Completed
Start date
July 21, 2025
Completion date
June 16, 2026
Enrollment
832 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19